Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Head of Bayer's crop unit quits in aftermath of profit rout

Published 09/11/2021, 07:03
Updated 09/11/2021, 08:43
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

By Ludwig Burger

FRANKFURT (Reuters) -Germany's Bayer (DE:BAYGN) said on Tuesday that Liam Condon, the head of its crop science unit which includes Monsanto (NYSE:MON), would quit at the end of the year following disappointing results.

The maker of pharmaceuticals and agricultural supplies said Condon wanted to pursue other career opportunities and Rodrigo Santos, the Crop Science Division's chief operating officer, would take over from him on Jan. 1.

The news came as Bayer lifted its overall group earnings guidance, helped by demand for its non-prescription pharmaceuticals and better-than-expected sales of eye drug Eylea.

The crop science division, however, has underperformed in recent years as Condon led it through tumultuous times, including the $63 billion takeover of U.S. seeds giant Monsanto. Orchestrated in 2016 by Condon's boss, Chief Executive Werner Baumann, the takeover later burdened Bayer with billions of dollars in legal costs over claims that Monsanto's main herbicide causes cancer.

Bayer last year fell behind its closest rival Corteva in the U.S. market in a race to launch new soy seeds that resist certain weedkillers. Crop science earnings in the second quarter of this year were burdened by rising raw material costs.

Trying to contain the litigation over herbicide Roundup, Bayer in August filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the glyphosate-based weedkiller.

CEO Baumann last year won a contract extension until 2024, but he said at the time that due to personal plans he had opted for a shorter term than was initially offered to him.

Chairman Norbert Winkeljohann, in the company's statement, thanked Condon for having “successfully led and strategically transformed the Crop Science Division,” but Bayer gave no further reasons for his departure.

Bayer also on Tuesday reported that third-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) before special items rose 16.4% to 2.09 billion euros ($2.41 billion), surpassing an average analyst forecast of 1.94 billion.

© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay

This was mainly due to prescriptions of Eylea, a treatment to avert blindness, gains at the group's unit making non-prescription remedies and at crop science. The bulk of the agriculture unit's annual earnings are generated during the first half, when farmers in the northern hemisphere typically purchase seeds and pesticides.

The group said full-year adjusted earnings per share were now expected to come in at between at 6.50 and 6.70 euros, when excluding currency swings. That is up from 6.39 euros in 2020 and compares with a previous target of 6.40 euros to 6.60 euros.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.